Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 13 peer-reviewed journal articles Updated
Neurology

The Diagnostic Process: Blood Tests, MRI, and Antibodies

At a Glance

NMOSD is diagnosed primarily using an AQP4-IgG antibody blood test (via a cell-based assay) and MRI scans showing long spinal cord lesions (LETM). Accurately distinguishing NMOSD from MS is critical, as common MS medications can cause severe and irreversible harm to NMOSD patients.

Diagnosing NMOSD is a detective process that combines your clinical history, advanced imaging, and highly specific blood tests. Because NMOSD was historically confused with Multiple Sclerosis (MS), your medical team must use modern diagnostic criteria to ensure you are receiving the right care. Misdiagnosis is more than a clerical error—it can lead to taking MS medications that are known to trigger severe, permanent relapses in NMOSD patients [1][2][3].

The “Gold Standard” Antibody Test

The most important tool in diagnosing NMOSD is a blood test for the AQP4-IgG antibody. This antibody is found in approximately 70–80% of people with the condition [4].

  • Cell-Based Assays (CBA): It is critical to know that not all antibody tests are equal. You should ask if your blood was tested using a cell-based assay (CBA). This method is the “gold standard” because it is much more accurate (higher sensitivity and specificity) than older methods like ELISA [5][6].
  • MOG-IgG Testing: If your AQP4 test is negative, your doctor should test for MOG-IgG antibodies. This identifies a related but different condition called MOGAD (MOG Antibody-Associated Disease), which can mimic NMOSD [5].

What Does Your MRI Show?

While MS and NMOSD both show up on an MRI, they leave very different “fingerprints” on the brain and spinal cord:

Feature NMOSD Hallmark MS Hallmark
Spinal Cord LETM (Longitudinally Extensive Transverse Myelitis): Lesions that span 3 or more vertebral segments in length [4][7]. Short lesions, usually spanning less than 1 or 2 vertebral segments [7].
Brain Stem Lesions in the Area Postrema (the part of the brain that controls vomiting/hiccups) [8][9]. Rarely involves the Area Postrema specifically.
Brain Large, “cloud-like” lesions or linear enhancement (bright lines) in the corpus callosum [10][11]. Small, oval-shaped lesions called “Dawson’s Fingers” that stick out from the brain’s ventricles [7].

Other Diagnostic Tools

Lumbar Puncture (Spinal Tap): Even though the definitive AQP4 test is a blood draw, doctors almost always perform a lumbar puncture during the initial workup. This helps rule out MS by checking your spinal fluid for “oligoclonal bands,” which are very common in MS but less common in NMOSD [4].

The Challenge of “Seronegative” NMOSD

If you test negative for AQP4-IgG antibodies, you are considered seronegative. You can still be diagnosed with NMOSD, but the requirements are much stricter [4]. Under the 2015 International Panel for NMO Diagnosis (IPND) guidelines, a seronegative diagnosis requires:

  1. At least two different core symptoms (such as optic neuritis AND a long spinal lesion) [4].
  2. Specific MRI findings that strongly suggest NMOSD over other conditions [4].
  3. The absolute exclusion of other diseases like MS, Sarcoidosis, or Lupus [4][12].

The Danger of Misdiagnosis

Getting the diagnosis right is an emergency because the treatments for MS and NMOSD are opposites in many ways. If a patient with NMOSD is mistakenly given common MS drugs—specifically interferon-beta, fingolimod, natalizumab, or dimethyl fumarate—it can cause “catastrophic” worsening [1][2]. These drugs can trigger attacks so severe they lead to respiratory failure or permanent paralysis [1][13]. If you were diagnosed with MS but your condition worsened rapidly after starting medication, this is a major “red flag” that should be discussed with your doctor immediately [1].

Common questions in this guide

What is the gold standard blood test for NMOSD?
The most accurate test for diagnosing NMOSD is the AQP4-IgG antibody test using a cell-based assay (CBA). This specific blood test can successfully identify the condition in 70 to 80 percent of patients.
How is an NMOSD MRI different from a Multiple Sclerosis MRI?
On a spinal MRI, NMOSD often causes long lesions spanning three or more vertebral segments, known as LETM. Brain MRIs may also show unique lesions in the area postrema, which differ from the small, oval lesions typical of MS.
What happens if my AQP4 antibody test is negative?
If you test negative for AQP4 antibodies, you are considered seronegative. You can still be diagnosed with NMOSD if you have specific symptoms, distinct MRI findings, and other diseases are ruled out. Your doctor may also test for MOG-IgG antibodies.
Why is it dangerous to misdiagnose NMOSD as MS?
Several common medications used to treat Multiple Sclerosis can cause severe, permanent relapses in NMOSD patients. An accurate diagnosis is essential to ensure you do not receive drugs that could trigger life-threatening attacks or paralysis.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which specific lab performed my antibody test, and was it a cell-based assay (CBA)?
  2. 2.If I tested negative for AQP4-IgG, did we also test for MOG-IgG antibodies?
  3. 3.Do my spinal MRI lesions meet the criteria for Longitudinally Extensive Transverse Myelitis (LETM)?
  4. 4.Are there any signs of 'Area Postrema' involvement or linear enhancement in my brain MRI?
  5. 5.Am I currently on any medications that are known to worsen NMOSD (like interferon-beta or natalizumab)?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (13)
  1. 1

    Catastrophic relapses following initiation of dimethyl fumarate in two patients with neuromyelitis optica spectrum disorder.

    Yamout BI, Beaini S, Zeineddine MM, Akkawi N

    Multiple sclerosis (Houndmills, Basingstoke, England) 2017; (23(9)):1297-1300 doi:10.1177/1352458517694086.

    PMID: 28391740
  2. 2

    Unexpected exacerbations following initiation of disease-modifying drugs in neuromyelitis optica spectrum disorder: Which factor is responsible, anti-aquaporin 4 antibodies, B cells, Th1 cells, Th2 cells, Th17 cells, or others?

    Kira JI

    Multiple sclerosis (Houndmills, Basingstoke, England) 2017; (23(9)):1300-1302 doi:10.1177/1352458517703803.

    PMID: 28391741
  3. 3

    Pediatric-Onset Neuromyelitis Optica Spectrum Disorder: Long-term Follow-up and Therapeutic Challenges in a Treatment-Resistant Case.

    Yetkin MF, Benli Ş, Mirza M

    Journal of child neurology 2025; (40(8)):704-707 doi:10.1177/08830738251340278.

    PMID: 40398846
  4. 4

    International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.

    Wingerchuk DM, Banwell B, Bennett JL, et al.

    Neurology 2015; (85(2)):177-89 doi:10.1212/WNL.0000000000001729.

    PMID: 26092914
  5. 5

    Emerging drugs for the treatment of adult MOG-IgG-associated diseases.

    Carnero Contentti E, Marrodan M, Correale J

    Expert opinion on emerging drugs 2021; (26(2)):75-78 doi:10.1080/14728214.2021.1919082.

    PMID: 33861167
  6. 6

    AQP4 Antibody Assay Sensitivity Comparison in the Era of the 2015 Diagnostic Criteria for NMOSD.

    Prain K, Woodhall M, Vincent A, et al.

    Frontiers in neurology 2019; (10()):1028 doi:10.3389/fneur.2019.01028.

    PMID: 31636597
  7. 7

    Spectrum of MRI brain lesion patterns in neuromyelitis optica spectrum disorder: a pictorial review.

    Wang KY, Chetta J, Bains P, et al.

    The British journal of radiology 2018; (91(1086)):20170690 doi:10.1259/bjr.20170690.

    PMID: 29388807
  8. 8

    Area postrema syndrome: A short history of a pearl in demyelinating diseases.

    Camara-Lemarroy CR, Burton JM

    Multiple sclerosis (Houndmills, Basingstoke, England) 2019; (25(3)):325-329 doi:10.1177/1352458518813105.

    PMID: 30463481
  9. 9

    Intractable Vomiting and Hiccups: An Atypical Presentation of Neuromyelitis Optica Spectrum Disorder.

    Sarna MK, Setia M, Rijhwani P, et al.

    The Journal of the Association of Physicians of India 2025; (73(4)):93-96 doi:10.59556/japi.73.0911.

    PMID: 40200627
  10. 10

    Neuromyelitis optica with linear enhancement of corpus callosum in brain magnetic resonance imaging with contrast: a case report.

    Sahraian MA, Moghadasi AN, Owji M, et al.

    Journal of medical case reports 2015; (9()):137 doi:10.1186/s13256-015-0613-9.

    PMID: 26059535
  11. 11

    Neuromyelitis optica spectrum disorder in the elderly associated with bronchiolitis obliterans organizing pneumonia.

    Ruisanchez Nieva A, Sanchez Menoyo JL, Escalza Cortina I, et al.

    Neurology. Clinical practice 2017; (7(5)):404-406 doi:10.1212/CPJ.0000000000000336.

    PMID: 29620080
  12. 12

    Seronegative neuromyelitis optica spectrum disorder with longitudinally extending transverse myelitis and optic neuritis: A case report.

    Khadka B, Bhattarai AM, Dhakal B, et al.

    Annals of medicine and surgery (2012) 2022; (78()):103757 doi:10.1016/j.amsu.2022.103757.

    PMID: 35600183
  13. 13

    Case Report: Severe rebound after withdrawal of fingolimod in a patient with neuromyelitis optica spectrum disorder.

    Lin W, Chou CH, Yang FC, et al.

    Frontiers in immunology 2023; (14()):1115120 doi:10.3389/fimmu.2023.1115120.

    PMID: 37122715

This page explains NMOSD diagnostic tests for educational purposes only. Always consult your neurologist or healthcare provider to properly interpret your specific MRI or laboratory results.

Get notified when new evidence is published on Neuromyelitis optica spectrum disorder.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.